Despite the efficacy of the antipsychotic clozapine in treating schizophrenia, research suggests that its use is somewhat limited. A new study investigates the role of demographic factors in this discrepancy. Analyzing six years of electronic health record data from more than 3,000 adults with schizophrenia in a multifacility health system, researchers found that Black patients with schizophrenia were less likely to receive a clozapine prescription than white patients. Further research is needed to better understand how race may impact the use of clozapine in an individual’s treatment plan. To learn more, see the study in Psychiatric Services.